Pfizer (PFE) Gets FDA Nod for Pneumococcal Vaccine Prevnar 20
-
Summary:
The FDA has approved Pfizer Inc’s (NYSE: PFE) Prevnar 20 (Pneumococcal 20-valent Conjugate Vaccine) to prevent invasive disease and pneumonia caused by the 20 common strains of Streptococcus pneumonia in adults. Following today’s FDA approval, the vaccine will now go to the U.S. Centers for Disease Control and Prevention (CDC). Advisory Committee on Immunization Practices (ACIP) is expected to meet in October to decide how it should be used in practice. Prevnar covers all 13 serotypes found in P
Pfizer (PFE) has received approval from the U.S. Food and Drug Administration (FDA) for its Pneumococcal 20-valent Conjugate vaccine, PREVNAR 20, for preventing invasive pneumococcal disease and pneumonia in adults aged 18 and above. Following this approval, the U.S. Centers for Disease Control an ...
Read Full News: https://finance.yahoo.com/news/pfizer-pfe-gets-fda-nod-141702567.html